Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

ADJU-PLATFORM Minimal Saponin-based Adjuvant Vaccine Platform

Coordinator
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune, Spain
Runs
1 March 2024 to 31 August 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069368

What the project is doing

In the project's own words, from its summary on CORDIS.

ADJU-PLATFORM seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the efficient production of optimised saponin adjuvants and improved cost-effective vaccines. We have recently developed in the laboratory a potent, safe, stable and streamlined platform based on an optimised version of the vaccine adjuvant QS-21 that has led to patent applications and raised the interest of the pharmaceutical industry.

In this PoC project, we aim to exploit our synthetic saponin technology to produce scalable adjuvant and vaccine candidates that outperform existing products more cost-effectively, lowering the risk profile of the commercialisation potential, while also achieving valorisation outcomes for market entry. The goal is to demonstrate our innovative minimal adjuvant platform in relevant settings for the advancement of novel adjuvant prototypes and molecular vaccines closer to the market.

The breakthrough innovation potential of ADJU-PLATFORM lies in the exploitation of this adjuvant vaccine platform for its application with additional formulation systems in a range of disease areas, expanding and improving the available vaccine solutions. The high purity and excellent chemical control over our synthetic platform compared to the heterogeneous natural product adjuvants, as well as its streamlined, modular nature and low-cost profile are distinctive attributes of our technology that will be valorised herein, making it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines.

The main objectives are (1) demonstrate our synthetic technology platform for the streamlined and efficient development of scalable adjuvant and vaccine solutions and (2) implement valorisation opportunities of our platform and products by establishing an optimal IPR strategy and a go-to-market roadmap for the commercialisation.

Topics

Who is involved

OrganisationCityCountryRole
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic BioguneDerio VizcayaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI